Monocarboxylate transporters 1 and 4 in tumor lactate exchange: Molecular mechanisms, pharmacological inhibition, and therapeutic translation
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Xinyu Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China. Hauptthemen laut MEDLINE: Monocarboxylic Acid Transporters, Symporters, Neoplasms, Muscle Proteins. Die Arbeit nennt 142 Literaturangaben. Gefördert von: Shaanxi Province Key Research and Development Projects.
Abstract (Originalsprache)
Lactate is no longer viewed merely as a glycolytic end product but as a metabolic substrate and signaling molecule that promotes tumor growth, metabolic cooperation, extracellular acidification, immune suppression, and treatment resistance. Monocarboxylate transporter 1 (MCT1) supports gradient-dependent lactate uptake or efflux, whereas monocarboxylate transporter 4 (MCT4) sustains lactate-proton export from hypoxic glycolytic cells, together coordinating intratumoral lactate exchange and pH homeostasis. However, an integrated framework is still lacking to distinguish transporter expression from functional lactate dependence and to connect mechanistic insights with cancer-specific pharmacological evidence. This review integrates the molecular architecture, proton-coupled transport mechanisms, substrate recognition, and chaperone-dependent trafficking of MCT1 and MCT4, and explains how their spatially distinct functions shape metabolic compartmentalization and tumor microenvironment remodeling. It further examines cancer-type-specific dependencies and distinguishes simple expression associations from experimentally supported reliance on lactate transport, with attention to extracellular acidification, angiogenesis, immune suppression, stromal remodeling, invasion, and therapeutic resistance. MCT-directed agents are systematically classified as nonselective, MCT1-selective, MCT4-selective, or dual/multi-isoform inhibitors and critically evaluated according to potency, selectivity, structural support, cellular target engagement, in vivo efficacy, resistance mechanisms, pharmacokinetics, safety, and clinical maturity. These data are integrated into a translational framework that separates transporter expression, functional lactate-transport dependence, pharmacological target engagement, and metabolic escape. Overall, actionable MCT dependence should be defined by membrane localization, lactate flux, limited compensatory capacity, and demonstrable target engagement rather than by transporter abundance alone, thereby informing biomarker-guided combinations and next-generation MCT-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China.
- The First Clinical Medical College, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China.
- School of Clinical Medicine, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China.
- College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave, Xi'an-Xianyang New Economic Zone, Shaanxi Province, China; Lushan Xinglin Institute for Medicinal Plants, Jiujiang Xinglin Key Laboratory for Tradi…
Förderung
- Shaanxi Province Key Research and Development Projects
Zitieren
APA
Chen, X., Lu, J., Chen, Y., Liu, X., Wu, Q., Jin, R., Guo, H., Zhang, Q., Zhao, P., & Wang, Y. (2026). Monocarboxylate transporters 1 and 4 in tumor lactate exchange: Molecular mechanisms, pharmacological inhibition, and therapeutic translation. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118554
Vancouver
Chen X, Lu J, Chen Y, Liu X, Wu Q, Jin R, et al. Monocarboxylate transporters 1 and 4 in tumor lactate exchange: Molecular mechanisms, pharmacological inhibition, and therapeutic translation. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118554
BibTeX
@article{Chen2026,
author = {Chen, Xinyu and Lu, Jiajie and Chen, Yu and Liu, Xinqun and Wu, Qunhuang and Jin, Ruyi and Guo, Hui and Zhang, Qiao and Zhao, Peng and Wang, Yuwei},
title = {Monocarboxylate transporters 1 and 4 in tumor lactate exchange: Molecular mechanisms, pharmacological inhibition, and therapeutic translation},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118554}
}
EUVIMED